

***Centers for Disease Control and Prevention  
Lipid Standardization Program***

**2026**

*certifies the*

**Medpace Pharmaceutical Sciences Co., Ltd  
Shanghai, China  
INT-418**

*This laboratory, under the direction of Dr. Tan Paul, has successfully met precision and accuracy criteria for standardization by the Centers for Disease Control and Prevention Lipid Standardization Program during the First Quarter of 2026 for the following analytical systems:*

<b>Instrument</b>	<b>Analyte</b>	<b>Method</b>
<b>Beckman AU 5800</b>	<b>TC</b>	<b>601 - Enzymatic</b>
<b>Beckman AU 5800</b>	<b>TG</b>	<b>602 - Enzymatic (Non Blanked)</b>
<b>Beckman AU 5800</b>	<b>HDLC</b>	<b>605 - Dextran Sulfate MW 50,000/Mg</b>



Hubert Vesper, PhD  
Director of CDC Clinical Standardization Programs

